Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Helix BioMedix Inc (HXBM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2012: -0.445x
Based on the latest financial reports, Helix BioMedix Inc (HXBM) has a cash flow conversion efficiency ratio of -0.445x as of September 2012.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-511.84K) by net assets ($1.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Helix BioMedix Inc - Cash Flow Conversion Efficiency Trend (2006–2023)
This chart illustrates how Helix BioMedix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Helix BioMedix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Helix BioMedix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digital Power Communications Co. Ltd.
KQ:026890
|
N/A |
|
INVESCO MORTGA.CAP.DL-01
F:7M20
|
N/A |
|
Federal Screw Works
PINK:FSCR
|
0.089x |
|
Jse Ltd
BE:JF6
|
N/A |
|
Alfa Financial Software Holdings PLC
LSE:ALFA
|
0.350x |
|
SHENZHOU INTL GROUP
BE:S6L
|
N/A |
|
Edgio Inc
NASDAQ:EGIO
|
-0.070x |
|
Nuveen Enhanced High Yield Municipal Bond Fund
NASDAQ:NMSSX
|
N/A |
Annual Cash Flow Conversion Efficiency for Helix BioMedix Inc (2006–2023)
The table below shows the annual cash flow conversion efficiency of Helix BioMedix Inc from 2006 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $2.96 Million | $-870.21K | -0.294x | -53.76% |
| 2022-12-31 | $3.80 Million | $-727.73K | -0.191x | -5.88% |
| 2021-12-31 | $4.73 Million | $-854.67K | -0.181x | +39.32% |
| 2020-12-31 | $2.24 Million | $-667.33K | -0.298x | +67.12% |
| 2011-12-31 | $2.54 Million | $-2.30 Million | -0.906x | -57.83% |
| 2010-12-31 | $4.87 Million | $-2.80 Million | -0.574x | -196.55% |
| 2009-12-31 | $-5.17 Million | $-3.07 Million | 0.594x | -67.57% |
| 2008-12-31 | $-1.71 Million | $-3.14 Million | 1.832x | +195.32% |
| 2007-12-31 | $1.67 Million | $-3.21 Million | -1.922x | -77.80% |
| 2006-12-31 | $2.80 Million | $-3.03 Million | -1.081x | -- |